Compounds > lomustine
Page last updated: 2024-10-30

lomustine and Kahler Disease

lomustine has been researched along with Kahler Disease in 22 studies

Research Excerpts

ExcerptRelevanceReference
"A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU)."9.06Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. ( Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S, 1988)
"In a randomised multicentre trial a combination of methylprednisolone, vincristine, CCNU, cyclophosphamide and melphalan (MOCCA) was compared with intermittent melphalan and prednisone (MP) as primary treatment in multiple myeloma."9.06Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. ( Ahrenberg, P; Ala-Harja, K; Almqvist, A; Apajalahti, J; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Palva, IP, 1987)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."9.05Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"To compare the efficacy and safety of BD regimen combined with cyclophosphamide(CTX) and pirarubicin chemotherapy(P-CAD) for patients with relapse/refractory multiple myeloma(MM)."7.83[Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma]. ( Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016)
"The results of a combination chemotherapy trial (melphalan, CCNU, vincristine, cyclophosphamide) involving 28 patients with stage III (n = 21) or stage II (n = 7) multiple myeloma suggest a high response rate, with a mean 71% malignant cell destruction in 78."7.66[Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases]. ( Bierling, P; Brun, B; Cordonnier, C; Dreyfus, B; Farcet, JP; Feuilhade, F; Kuentz, M; Man, NG; Reyes, F; Rochant, H; Vernant, JP, 1983)
"In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma."5.07Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group. ( Ala-Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Palva, IP, 1993)
"80 patients with resistant or relapsing multiple myeloma received a combination of vincristine, cyclophosphamide, lomustine, melphalan and methylprednisolone (MOCCA) as a second-line chemotherapy."5.07Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group. ( , 1992)
"A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU)."5.06Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. ( Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S, 1988)
"In a randomised multicentre trial a combination of methylprednisolone, vincristine, CCNU, cyclophosphamide and melphalan (MOCCA) was compared with intermittent melphalan and prednisone (MP) as primary treatment in multiple myeloma."5.06Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. ( Ahrenberg, P; Ala-Harja, K; Almqvist, A; Apajalahti, J; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Palva, IP, 1987)
"A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0."5.05Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982)
"A number of cooperative-group and single-institution studies have shown that BCNU used in combination with prednisone alone or with melphalan,cyclophosphamide, and prednisone is useful for remission induction in patients with previously untreated multiple myeloma."5.04Nitrosoureas in multiple myeloma. ( Salmon, SE, 1976)
"To compare the efficacy and safety of BD regimen combined with cyclophosphamide(CTX) and pirarubicin chemotherapy(P-CAD) for patients with relapse/refractory multiple myeloma(MM)."3.83[Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma]. ( Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016)
"To evaluate the impact of an additive therapy with an oral enzyme (OE) preparation given for more than 6 months additionally to standard combination chemotherapy (vincristine/melphalan/cyclophosphamide/prednisone (VMCP)- or methylprednisolone/ vincristine/CCNU/cyclophosphamide/melphalan (MOCCA)-regimen) in the primary treatment of patients with multiple myeloma stages I-III."3.71Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. ( Bock, PR; Chabronová, I; Dedík, L; Gazová, S; Hanisch, J; Holomanova, D; Hrubisko, M; Mistrík, M; Sakalová, A; Schiess, W, 2001)
"The results of a combination chemotherapy trial (melphalan, CCNU, vincristine, cyclophosphamide) involving 28 patients with stage III (n = 21) or stage II (n = 7) multiple myeloma suggest a high response rate, with a mean 71% malignant cell destruction in 78."3.66[Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases]. ( Bierling, P; Brun, B; Cordonnier, C; Dreyfus, B; Farcet, JP; Feuilhade, F; Kuentz, M; Man, NG; Reyes, F; Rochant, H; Vernant, JP, 1983)
"Patients aged 70 yr or older with multiple myeloma were treated, when suitable, according to concurrent trial protocols for younger patients, with the exception that the cytostatic regimen was not allocated at random."2.66Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. ( Ahrenberg, P; Ala-Harja, K; Almqvist, A; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Kilpi, H; Palva, IP, 1989)
"50 patients were treated for multiple myeloma with 5-drug combination chemotherapy between Jan 1979 and Feb 1980."1.28Improved long-term survival in multiple myeloma. Finnish Leukaemia Group. ( , 1989)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-199013 (59.09)18.7374
1990's3 (13.64)18.2507
2000's4 (18.18)29.6817
2010's2 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, YF1
Xu, WJ1
Chen, YL1
Ma, XH1
Qiu, ZY1
Ren, CA1
Fukumoto, S1
Hanazono, K1
Kawasaki, N1
Hori, Y1
Higuchi, S1
Sasaki, T1
Temma, K1
Uchide, T1
Brun, B1
Kuentz, M1
Man, NG1
Feuilhade, F1
Bierling, P1
Vernant, JP1
Farcet, JP1
Cordonnier, C1
Reyes, F1
Dreyfus, B1
Rochant, H1
Le Loët, X1
Monconduit, M1
Menard, JF1
Deshayes, P1
Grobois, B1
Tanguy, A1
Prevost, E1
Piguet, H1
Weiss, RB1
Issell, BF1
Cornwell, GG2
Pajak, TF2
Kochwa, S2
McIntyre, OR3
Glowienka, LP2
Brunner, K2
Rafla, S2
Silver, RT1
Cooper, MR2
Henderson, E2
Kyle, RA1
Haurani, FI1
Cuttner, J1
Sakalová, A2
Holománová, D2
Mikulecký, M1
Mistrík, M2
Lipsic, T1
Steruská, M1
Palva, IP3
Ala-Harja, K3
Almqvist, A3
Elonen, E1
Hallman, H2
Hänninen, A3
Ilvonen, M3
Isomaa, B3
Jouppila, J2
Järvenpää, E3
Parameswaran, R1
Giles, C1
Boots, M1
Littlewood, TJ1
Mills, MJ1
Kelsey, SM1
Samson, D1
Rodon, P1
Linassier, C1
Gauvain, JB1
Benboubker, L1
Goupille, P1
Maigre, M1
Luthier, F1
Dugay, J1
Lucas, V1
Colombat, P1
Colombi, M1
Guffanti, A1
Alietti, A1
Latargia, ML1
Vener, C1
Maiolo, AT1
Baldini, L1
Bock, PR1
Dedík, L1
Hanisch, J1
Schiess, W1
Gazová, S1
Chabronová, I1
Hrubisko, M1
Hartman, HA1
Skoog, D1
Foley, JF1
Stone, DB1
Salmon, SE1
Ahrenberg, P2
Kilpi, H1
Coleman, M1
Apajalahti, J1

Reviews

3 reviews available for lomustine and Kahler Disease

ArticleYear
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
    Cancer treatment reviews, 1982, Volume: 9, Issue:4

    Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod

1982
Multiple myeloma in elderly patients: presenting features and outcome.
    European journal of haematology, 2001, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Comorbidity

2001
Current concepts in cancer. Multiple myeloma.
    The New England journal of medicine, 1979, Jul-26, Volume: 301, Issue:4

    Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobul

1979

Trials

10 trials available for lomustine and Kahler Disease

ArticleYear
Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    British journal of cancer, 1980, Volume: 42, Issue:6

    Topics: Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Studi

1980
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
    Cancer, 1982, Nov-01, Volume: 50, Issue:9

    Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female;

1982
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
    European journal of haematology, 1993, Volume: 51, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leuke

1993
OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma.
    Leukemia & lymphoma, 2000, Volume: 40, Issue:1-2

    Topics: Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau

2000
Nitrosoureas in multiple myeloma.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Human

1976
Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
    European journal of haematology, 1992, Volume: 48, Issue:1

    Topics: Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resi

1992
Treatment of multiple myeloma in old patients. Finnish Leukaemia Group.
    European journal of haematology, 1989, Volume: 43, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; L

1989
Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Drug Administr

1988
Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
    European journal of haematology, 1987, Volume: 38, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S

1987
Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
    Scandinavian journal of haematology, 1985, Volume: 35, Issue:2

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Lomustine; Male; Melphalan;

1985

Other Studies

9 other studies available for lomustine and Kahler Disease

ArticleYear
[Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin

2016
Anaplastic atypical myeloma with extensive cutaneous involvement in a dog.
    The Journal of veterinary medical science, 2012, Volume: 74, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Fatal Outcome; Lomustin

2012
[Multiple myeloma with high tumoral mass. Treatment combining melphalan, cyclophosphamide, vincristine, CCNU and prednisone. 35 cases].
    Presse medicale (Paris, France : 1983), 1983, Apr-30, Volume: 12, Issue:19

    Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lom

1983
[Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Revue du rhumatisme et des maladies osteo-articulaires, 1984, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; France; Humans; Lomustine;

1984
Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Neoplasma, 1993, Volume: 40, Issue:6

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female;

1993
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma.
    British journal of haematology, 2000, Volume: 109, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti

2000
Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47 Suppl

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothera

2001
Response to adriamycin and CCNU in a patient with IgD multiple myeloma and myelofibrosis.
    The Nebraska medical journal, 1979, Volume: 64, Issue:7

    Topics: Doxorubicin; Humans; Immunoglobulin D; Immunoglobulin lambda-Chains; Lomustine; Male; Middle Aged; M

1979
Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
    European journal of haematology, 1989, Volume: 43, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Finland; Humans; Lomustine; Melpha

1989